CG
PRTK

Cutler Group’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Cutler Group’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-9,100
Closed -$2K – 5450
2017
Q4 		$2K Sell
9,100
-48,200
-84% -$1.01M ﹤0.01% 4263
2017
Q3 		$274K Buy
57,300
+29,700
+108% +$691K 0.01% 970
2017
Q2 		$67K Buy
27,600
+25,700
+1,353% +$568K ﹤0.01% 2194
2017
Q1 		$6K Sell
1,900
-2,100
-53% -$33.1K ﹤0.01% 4621
2016
Q4 		$7K Sell
4,000
-5,300
-57% -$68.8K ﹤0.01% 4651
2016
Q3 		$4K Buy
9,300
+8,900
+2,225% +$118K ﹤0.01% 5224
2016
Q2 		$1K Buy
+400
New +$5.89K ﹤0.01% 6351

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Cutler Group's PRTK Position: Q4 2018 in Review

Cutler Group sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2018, closing a stake of 100 shares.

Cutler Group first reported a position in PRTK in Q2 2016 and held it in 10 quarters. The position peaked at $625K in Q2 2017. 102 funds tracked by Wall St. Rank hold PRTK as of Q4 2018.

  • Cutler Group reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Cutler Group sold 100 Paratek Pharmaceuticals, Inc. shares in Q4 2018.
  • Cutler Group first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2016 and held it in 10 quarters.
  • Cutler Group's Paratek Pharmaceuticals, Inc. position peaked at $625K in Q2 2017.
  • 102 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2018.

Based on Cutler Group's 13F filing for Q4 2018, filed 5 Feb 2019.